KRAS and non-small cell lung carcinoma: The two-year pooled analysis of the CodeBreaK 100 phase 1/2 clinical trial showed that almost 25% of these previously treated advanced stage KRAS G12C-mutant NSCLC patients derived long-term benefit from additional sotorasib treatment, with few late-onset treatment-related toxicities (41).